The use of imaging and biomarkers in diagnosing Barrett's esophagus and predicting the risk of neoplastic progression

Expert Review of Molecular Diagnostics

Volumn 14, Issue 5, 2014, Pages 575-591

  Ramzan, Zeeshan ^a   Nassri, Ammar B ^a   Huerta, Sergio ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Barrett's esophagus; Biomarkers; DNA content abnormalities; Dysplasia; Endoscopy; Epigenetics; Esophageal adenocarcinoma; Imaging; LOH; MiRNA

Indexed keywords

DNA; FLUORESCENT DYE; HISTONE; MICRORNA; MINICHROMOSOME MAINTENANCE PROTEIN 2; PEPTIDE; TRANSCRIPTION FACTOR CDX1; TRANSCRIPTION FACTOR CDX2; TUMOR MARKER; CELL CYCLE PROTEIN;

ANEUPLOIDY; AUTOFLUORESCENCE IMAGING; BARRETT ESOPHAGUS; BODY FLUID; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RISK; CHROMOENDOSCOPY; CLONAL EVOLUTION; CYTOSPONGE; DIAGNOSTIC EQUIPMENT; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DNA CONTENT; DNA METHYLATION; EPIGENETICS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; GENE EXPRESSION; HETEROZYGOSITY LOSS; HISTONE ACETYLATION; HUMAN; MOLECULAR PROBE; OPTICAL COHERENCE TOMOGRAPHY; PRACTICE GUIDELINE; PREDICTIVE VALUE; REVIEW; SENSITIVITY AND SPECIFICITY; TETRAPLOIDY; WHITE LIGHT ENDOSCOPY; ADENOCARCINOMA; ESOPHAGEAL NEOPLASMS; FLUORESCENCE IMAGING; GENETIC EPIGENESIS; GENETICS; METABOLISM; PATHOLOGY; RISK FACTOR;

ADENOCARCINOMA; BARRETT ESOPHAGUS; BIOMARKERS, TUMOR; CELL CYCLE PROTEINS; EPIGENESIS, GENETIC; ESOPHAGEAL NEOPLASMS; HUMANS; MICRORNAS; OPTICAL IMAGING; RISK FACTORS;

EID: 84901251923     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2014.919856     Document Type: Review

References (110)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63(1):11-30
2. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97(2):142-6 (Pubitemid 40277094
3. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61(2):69-90
4. Rastogi A, Puli S, El-Serag HB, et al. Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: A meta-Analysis. Gastrointest Endosc 2008;67(3):394-8 (Pubitemid 351260043
5. Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: A meta-Analysis. Gut 2012; 61(7):970-6
6. Rugge M, Fassan M, Cavallin F, Zaninotto G. Re: Risk of malignant progression in Barrett's esophagus patients: Results from a large population-based study. J Natl Cancer Inst 2012;104(22):1771-2
7. Sikkema M, de Jonge PJ, Steyerberg EW, Kuipers EJ. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: A systematic review and meta-Analysis. Clin Gastroenterol Hepatol 2010;8(3):235-44.quiz e232
8. Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011;365(15):1375-83
9. Bennett C, Vakil N, Bergman J, et al. Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology 2012;143(2):336-46
10. Tharavej C, Hagen JA, Peters JH, et al. Predictive factors of coexisting cancer in Barrett's high-grade dysplasia. Surg Endosc 2006;20(3):439-43 (Pubitemid 43260503
11. Wang KK, Okoro N, Prasad G, et al. Endoscopic evaluation and advanced imaging of Barrett's esophagus. Gastrointest Endosc Clin N Am 2011;21(1):39-51
12. Hoffman A, Korczynski O, Tresch A, et al. Acetic acid compared with i-scan imaging for detecting Barrett's esophagus: A randomized, comparative trial. Gastrointest Endosc 2014;79(1):46-54
13. Kara MA, Ennahachi M, Fockens P, et al. Detection and classification of the mucosal and vascular patterns (mucosal morphology) in Barrett's esophagus by using narrow band imaging. Gastrointest Endosc 2006;64(2): 155-66 (Pubitemid 44062482
14. Pohl J, May A, Rabenstein T, et al. Computed virtual chromoendoscopy: A new tool for enhancing tissue surface structures. Endoscopy 2007;39(1):80-3 (Pubitemid 46403132
15. Lovat LB, Johnson K, Mackenzie GD, et al. Elastic scattering spectroscopy accurately detects high grade dysplasia and cancer in Barrett's oesophagus. Gut 2006;55(8): 1078-83 (Pubitemid 44085671
16. Wallace MB, Perelman LT, Backman V, et al. Endoscopic detection of dysplasia in patients with Barrett's esophagus using light-scattering spectroscopy. Gastroenterology 2000;119(3):677-82
17. Mutyal NN, Radosevich A, Gould B, et al. A fiber optic probe design to measure depth-limited optical properties in-vivo with low-coherence enhanced backscattering (LEBS) spectroscopy. Opt Express 2012; 20(18):19643-57
18. Qiu L, Pleskow DK, Chuttani R, et al. Multispectral scanning during endoscopy guides biopsy of dysplasia in Barrett's esophagus. Nat Med 2010;16(5):603-6 .601p following 606
19. Georgakoudi I, Van Dam J. Characterization of dysplastic tissue morphology and biochemistry in Barrett's esophagus using diffuse reflectance and light scattering spectroscopy. Gastrointest Endosc Clin N Am 2003;13(2):297-308 (Pubitemid 36605246
20. Roy HK, Backman V. Spectroscopic applications in gastrointestinal endoscopy. Clin Gastroenterol Hepatol 2012;10(12): 1335-41
21. Wax A, Terry NG, Dellon ES, Shaheen NJ. Angle-resolved low coherence interferometry for detection of dysplasia in Barrett's esophagus. Gastroenterology 2011;141(2): 443-7.447 e441-442
22. Krafft C, Dietzek B, Schmitt M, Popp J. Raman and coherent anti-Stokes Raman scattering microspectroscopy for biomedical applications. J Biomed Opt 2012;17(4): 040801
23. Hossain MK, Kitahama Y, Huang GG, et al. Surface-enhanced Raman scattering: Realization of localized surface plasmon resonance using unique substrates and methods. Anal Bioanal Chem 2009;394(7): 1747-60
24. Almond LM, Hutchings J, Kendall C, et al. Assessment of a custom-built Raman spectroscopic probe for diagnosis of early oesophageal neoplasia. J Biomed Opt 2012; 17(8):081421
25. Almond LM, Hutchings J, Lloyd G, et al. Endoscopic Raman spectroscopy enables objective diagnosis of dysplasia in Barrett's esophagus. Gastrointest Endosc 2014;79(1): 37-45
26. Falk GW. Autofluorescence endoscopy. Gastrointest Endosc Clin N Am 2009; 19(2):209-20
27. Curvers WL, Alvarez Herrero L, Wallace MB, et al. Endoscopic tri-modal imaging is more effective than standard endoscopy in identifying early-stage neoplasia in Barrett's esophagus. Gastroenterology 2010;139(4):1106-14
28. Curvers WL, van Vilsteren FG, Baak LC, et al. Endoscopic trimodal imaging versus standard video endoscopy for detection of early Barrett's neoplasia: A multicenter, randomized, crossover study in general practice. Gastrointest Endosc 2011;73(2): 195-203
29. Bouma BE, Yun SH, Vakoc BJ, et al. Fourier-domain optical coherence tomography: Recent advances toward clinical utility. Curr Opin Biotechnol 2009;20(1): 111-18
30. Sauk J, Coron E, Kava L, et al. Interobserver agreement for the detection of Barrett's esophagus with optical frequency domain imaging. Dig Dis Sci 2013;58(8): 2261-5
31. Kadri SR, Lao-Sirieix P, O'Donovan M, et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: Cohort study. BMJ 2010;341:c4372
32. Kadri S, Lao-Sirieix P, Fitzgerald RC. Developing a nonendoscopic screening test for Barrett's esophagus. Biomark Med 2011; 5(3):397-404
33. Lao-Sirieix P, Boussioutas A, Kadri SR, et al. Non-endoscopic screening biomarkers for Barrett's oesophagus: From microarray analysis to the clinic. Gut 2009;58(11): 1451-9
34. Li M, Anastassiades CP, Joshi B, et al. Affinity peptide for targeted detection of dysplasia in Barrett's esophagus. Gastroenterology 2010;139(5):1472-80
35. Sturm MB, Joshi BP, Lu S, et al. Targeted imaging of esophageal neoplasia with a fluorescently labeled peptide: First-in-human results. Sci Transl Med 2013;5(184): 184ra161
36. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429(6990):457-63 (Pubitemid 38715140
37. Gibney ER, Nolan CM. Epigenetics and gene expression. Heredity (Edinb) 2010;105:4-13
38. Agarwal A, Polineni R, Hussein Z, et al. Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma. Int J Clin Exp Pathol 2012;5(5):382-96
39. Hamilton JP. Epigenetics: Principles and practice. Dig Dis 2011;29(2):130-5
40. Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol 2010;28(10):1057-68
41. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011;17(3):330-9
42. Clement G, Braunschweig R, Pasquier N, et al. Methylation of APC, TIMP3, and TERT: A new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation. J Pathol 2006;208(1):100-7 (Pubitemid 43025708
43. Jin Z, Cheng Y, Gu W, et al. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res 2009;69(10): 4112-15
44. Tischoff I, Hengge UR, Vieth M, et al. Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma. Gut 2007;56(8):1047-53 (Pubitemid 47123231
45. Kaz AM, Grady WM. Epigenetic biomarkers in esophageal cancer. Cancer Lett 2014;342(2):193-9
46. Bian YS, Osterheld MC, Fontolliet C, et al. p16 Inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus. Gastroenterology 2002;122(4): 1113-21 (Pubitemid 34267292
47. Eads CA, Lord RV, Wickramasinghe K, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 2001;61(8):3410-18 (Pubitemid 32695034
48. Wong DJ, Paulson TG, Prevo LJ, et al. p16 (INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001;61(22):8284-9
49. Xu E, Gu J, Hawk ET, et al. Genome-wide methylation analysis shows similar patterns in Barrett's esophagus and esophageal adenocarcinoma. Carcinogenesis 2013; 34(12):2750-6
50. Ong C-AJ. Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: Predictors of progression and prognosis. World J Gastroenterol 2010;16(45):5669
51. Alvi MA, Liu X, O'Donovan M, et al. DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett's esophagus. Clin Cancer Res 2013;19(4):878-88
52. Wang JS, Guo M, Montgomery EA, et al. DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in Barrett's esophagus. Am J Gastroenterol 2009;104(9):2153-60
53. Schulmann K, Sterian A, Berki A, et al. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-Associated neoplastic progression and predicts progression risk. Oncogene 2005;24(25): 4138-48
54. Sato F, Jin Z, Schulmann K, et al. Three-Tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features. PLoS One 2008;3(4):e1890
55. Russo A, Bronte G, Cabibi D, et al. The molecular changes driving the carcinogenesis in Barrett's esophagus: Which came first, the chicken or the egg?. Crit Rev Oncol Hematol 2013;86(3):278-89
56. Smith E, De Young NJ, Pavey SJ, et al. Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma. Mol Cancer 2008;7:75
57. Agarwal R, Jin Z, Yang J, et al. Epigenomic program of Barrett's-Associated neoplastic progression reveals possible involvement of insulin signaling pathways. Endocr Relat Cancer 2012;19(1):L5-9
58. Alvarez H, Opalinska J, Zhou L, et al. Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis. PLoS Genet 2011;7(3):e1001356
59. Wu W, Bhagat TD, Yang X, et al. Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1, in Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology 2013; 144(5):956-66.e954
60. Zhang S, Wang XI. SIRT1 is a useful biomarker for high-grade dysplasia and carcinoma in Barrett's esophagus. Ann Clin Lab Sci 2013;43(4):373-7
61. Teodori L, Gohde W, Persiani M, et al. DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus: Thirteen-year follow-up study on a cohort of patients. Cytometry 1998;34(6):257-63
62. Reid BJ, Blount PL, Rubin CE, et al. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: Prospective endoscopic surveillance of a cohort. Gastroenterology 1992;102(4 Pt 1): 1212-19
63. Reid BJ, Levine DS, Longton G, et al. Predictors of progression to cancer in Barrett's esophagus: Baseline histology and flow cytometry identify low-And high-risk patient subsets. Am J Gastroenterol 2000; 95(7):1669-76 (Pubitemid 30485000
64. Rabinovitch PS, Longton G, Blount PL, et al. Predictors of progression in Barrett's esophagus III: Baseline flow cytometric variables. Am J Gastroenterol 2001;96(11): 3071-83 (Pubitemid 33095344
65. Galipeau PC, Cowan DS, Sanchez CA, et al. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci USA 1996;93(14):7081-4
66. Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression in Barrett's esophagus II: Baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001;96(10):2839-48
67. Bellini MF, Cadamuro AC, Succi M, et al. Alterations of the TP53 gene in gastric and esophageal carcinogenesis. J Biomed Biotechnol 2012;2012:891961
68. Barrett MT, Sanchez CA, Galipeau PC, et al. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene 1996;13(9): 1867-73 (Pubitemid 26397445
69. Galipeau PC, Li X, Blount PL, et al. NSAIDs modulate CDKN2A, TP53, and DNA Content Risk for Progression to esophageal adenocarcinoma. PLoS Med 2007;4(2):e67
70. Younes M, Lebovitz RM, Lechago LV, Lechago J. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: A follow-up study. Gastroenterology 1993;105(6):1637-42
71. Murray L, Sedo A, Scott M, et al. TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort. Gut 2006; 55(10):1390-7 (Pubitemid 44476779
72. Weston AP, Banerjee SK, Sharma P, et al. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: Immunohistochemical marker predictive of progression. Am J Gastroenterol 2001;96(5): 1355-62 (Pubitemid 32455059
73. Fang M, Lew E, Klein M, et al. DNA abnormalities as marker of risk for progression of Barrett's esophagus to adenocarcinoma: Image cytometric DNA analysis in formalin-fixed tissues. Am J Gastroenterol 2004;99(10):1887-94 (Pubitemid 39421229
74. Vogt N, Schonegg R, Gschossmann JM, Borovicka J. Benefit of baseline cytometry for surveillance of patients with Barrett's esophagus. Surg Endosc 2010;24(5): 1144-50
75. Bird-Lieberman EL, Dunn JM, Coleman HG, et al. Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus. Gastroenterology 2012;143(4):927-35.e923
76. Sakai NS, Samia-Aly E, Barbera M, Fitzgerald RC. A review of the current understanding and clinical utility of miRNAs in esophageal cancer. Semin Cancer Biol 2013;23(6 Pt B):512-21
77. Fang Y, Fang D, Hu J. MicroRNA and its roles in esophageal cancer. Med Sci Monit 2012;18(3):RA22-30
78. Yang H, Gu J, Wang KK, et al. MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res 2009;15(18):5744-52
79. Feber A, Xi L, Luketich JD, et al. MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg 2008; 135(2):255-60.discussion 260
80. Saad R, Chen Z, Zhu S, et al. Deciphering the unique microRNA signature in human esophageal adenocarcinoma. PLoS One 2013;8(5):e64463
81. Liu SG, Qin XG, Zhao BS, et al. Differential expression of miRNAs in esophageal cancer tissue. Oncol Lett 2013; 5(5):1639-42
82. Weber JA, Baxter DH, Zhang S, et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010;56(11):1733-41
83. Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010;50(4):298-301
84. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105(30): 10513-18
85. Xie Z, Chen G, Zhang X, et al. Salivary microRNAs as promising biomarkers for detection of esophageal cancer. PLoS One 2013;8(4):e57502
86. Leidner RS, Ravi L, Leahy P, et al. The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett's esophageal carcinogenesis. Genes chromosomes Cancer 2012;51(5):473-9
87. Smith CM, Watson DI, Leong MP, et al. miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus. World J Gastroenterol 2011; 17(8):1036-44
88. Revilla-Nuin B, Parrilla P, Lozano JJ, et al. Predictive value of MicroRNAs in the progression of barrett esophagus to adenocarcinoma in a long-Term follow-up study. Ann Surg 2013;257(5):886-93
89. Wu X, Ajani JA, Gu J, et al. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer Prev Res (Phila) 2013;6(3):196-205
90. Sirieix PS, O'Donovan M, Brown J, et al. Surface expression of minichromosome maintenance proteins provides a novel method for detecting patients at risk for developing adenocarcinoma in Barrett's esophagus. Clin Cancer Res 2003;9(7): 2560-6 (Pubitemid 36842097
91. Lao-Sirieix P, Lovat L, Fitzgerald RC. Cyclin A immunocytology as a risk stratification tool for Barrett's esophagus surveillance. Clin Cancer Res 2007; 13(2 Pt 1):659-65 (Pubitemid 46225374
92. Bani-Hani K, Martin IG, Hardie LJ, et al. Prospective study of cyclin D1 overexpression in Barrett's esophagus: Association with increased risk of adenocarcinoma. J Natl Cancer Inst 2000; 92(16):1316-21 (Pubitemid 30660591
93. Chen JQ, Liu CJ, Wen HX, et al. Changes in the expression of cyclin G2 in esophageal cancer cell and its significance. Tumour Biol 2013;35(4):3355-62
94. Ma L, Juttner M, Kullak-Ublick GA, Eloranta JJ. Regulation of the gene encoding the intestinal bile acid transporter ASBT by the caudal-Type homeobox proteins CDX1 and CDX2. Am J Physiol Gastrointest Liver Physiol 2012;302(1): G123-33
95. Hayes S, Ahmed S, Clark P. Immunohistochemical assessment for Cdx2 expression in the Barrett metaplasia-dysplasia-Adenocarcinoma sequence. J Clin Pathol 2011;64(2):110-13
96. Souza RF, Krishnan K, Spechler SJ. Acid, bile, and CDX: The ABCs of making Barrett's metaplasia. Am J Physiol Gastrointest Liver Physiol 2008;295(2): G211-18
97. Merlo LM, Shah NA, Li X, et al. A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev Res (Phila) 2010;3(11):1388-97
98. Maley CC, Galipeau PC, Finley JC, et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 2006;38(4):468-73
99. Pacha A GT, Maley CC, Krishnadath KK. Su1911 increasing clonal diversity predicts progression in Barrett esophagus patients, results from a phase IV 5 year prospective follow up study. Abstract Gastroenterology 2012;142(5):S-534
100. Illig R, Klieser E, Kiesslich T, Neureiter D. GERD-Barrett- Adenocarcinoma: Do we have suitable prognostic and predictive molecular markers?. Gastroenterol Res Pract 2013;2013:643084
101. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144(5):646-74
102. Chen M, Huang J, Zhu Z, et al. Systematic review and meta-Analysis of tumor biomarkers in predicting prognosis in esophageal cancer. BMC Cancer 2013; 13(1):539
103. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 2014;63(1):7-42
104. de Jonge PJ, van Blankenstein M, Grady WM, Kuipers EJ. Barrett's oesophagus: Epidemiology, cancer risk and implications for management. Gut 2014; 63(1):191-202
105. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93(14):1054-61 (Pubitemid 32717537
106. Mathe EA, Nguyen GH, Bowman ED, et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: Associations with survival. Clin Cancer Res 2009;15(19):6192-200
107. Kan T, Sato F, Ito T, et al. The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim. Gastroenterology 2009;136(5):1689-700
108. Kastelein F, Biermann K, Steyerberg EW, et al. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus. Gut 2013;62(12): 1676-83
109. Sikkema M, Kerkhof M, Steyerberg EW, et al. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: A case-control study. Am J Gastroenterol 2009;104(11):2673-80
110. Skacel M, Petras RE, Rybicki LA, et al. p53 expression in low grade dysplasia in Barrett's esophagus: Correlation with interobserver agreement and disease progression. Am J Gastroenterol 2002; 97(10):2508-13